Literature DB >> 21049078

HLA Genotyping and Antibody Characterization Using the Luminex™ Multiplex Technology.

Falko Markus Heinemann1.   

Abstract

The Luminex-based human leukocyte antigen (HLA) antibody screening technology is widespread used in laboratories affiliated to kidney transplantation programs and enables both screening (i.e. the definition of positive or negative antibody status) and antibody identification with high sensitivity and specificity. HLA typing at different levels of resolution with Luminex technology uses sequence-specific oligonucleotide probes bound to color-coded microbeads in order to identify HLA alleles encoded by the DNA sample. In general, the Luminex technology for histocompatibility analyses provides rapid sample processing in a 96-well format combined with limited technical complexity which means high cost efficiency.

Entities:  

Year:  2009        PMID: 21049078      PMCID: PMC2941832          DOI: 10.1159/000228834

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  7 in total

Review 1.  Humoral theory of transplantation: further evidence.

Authors:  Paul I Terasaki; Junchao Cai
Journal:  Curr Opin Immunol       Date:  2005-10       Impact factor: 7.486

2.  Antibodies against MICA antigens and kidney-transplant rejection.

Authors:  Yizhou Zou; Peter Stastny; Caner Süsal; Bernd Döhler; Gerhard Opelz
Journal:  N Engl J Med       Date:  2007-09-27       Impact factor: 91.245

3.  Significance of the positive crossmatch test in kidney transplantation.

Authors:  R Patel; P I Terasaki
Journal:  N Engl J Med       Date:  1969-04-03       Impact factor: 91.245

4.  Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry.

Authors:  Yizhou Zou; Falko M Heinemann; Hans Grosse-Wilde; Guido Sireci; Zhengnan Wang; Bhavna Lavingia; Peter Stastny
Journal:  Hum Immunol       Date:  2006-03-30       Impact factor: 2.850

Review 5.  Optimal HLA matching in hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  Curr Opin Immunol       Date:  2008-08-08       Impact factor: 7.486

6.  A second lineage of mammalian major histocompatibility complex class I genes.

Authors:  S Bahram; M Bresnahan; D E Geraghty; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

7.  Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts.

Authors:  Falko M Heinemann; Ioana Roth; Vera Rebmann; Marie-Luise Arnold; Oliver Witzke; Benjamin Wilde; Bernd M Spriewald; Hans Grosse-Wilde
Journal:  Hum Immunol       Date:  2007-03-21       Impact factor: 2.850

  7 in total
  11 in total

Review 1.  HLA testing in the molecular diagnostic laboratory.

Authors:  Kathleen Madden; Devon Chabot-Richards
Journal:  Virchows Arch       Date:  2018-12-04       Impact factor: 4.064

2.  The 'Whole Genome Age'

Authors:  Peter Bugert
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

3.  Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells.

Authors:  Hadi Karimzadeh; Muthamia M Kiraithe; Anna D Kosinska; Manuel Glaser; Melanie Fiedler; Valerie Oberhardt; Elahe Salimi Alizei; Maike Hofmann; Juk Yee Mok; Melanie Nguyen; Wim J E van Esch; Bettina Budeus; Jan Grabowski; Maria Homs; Antonella Olivero; Hossein Keyvani; Francisco Rodríguez-Frías; David Tabernero; Maria Buti; Andreas Heinold; Seyed Moayed Alavian; Tanja Bauer; Julian Schulze Zur Wiesch; Bijan Raziorrouh; Daniel Hoffmann; Antonina Smedile; Mario Rizzetto; Heiner Wedemeyer; Jörg Timm; Iris Antes; Christoph Neumann-Haefelin; Ulrike Protzer; Michael Roggendorf
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

4.  Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment.

Authors:  Jinglan Zhang; Anastasia Fedick; Stephanie Wasserman; Geping Zhao; Lisa Edelmann; Erwin P Bottinger; Ruth Kornreich; Stuart A Scott
Journal:  J Mol Diagn       Date:  2016-01-07       Impact factor: 5.568

Review 5.  Developing pharmacogenetic screening methods for an emergent country: Vietnam.

Authors:  Dinh Van Nguyen; Christopher Vidal; Hieu Chi Chu; Sheryl van Nunen
Journal:  World Allergy Organ J       Date:  2019-06-06       Impact factor: 4.084

6.  Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients.

Authors:  Monika Lindemann; Simon Oesterreich; Benjamin Wilde; Ute Eisenberger; Nils Muelling; Peter A Horn; Falko M Heinemann; Oliver Witzke
Journal:  Vaccines (Basel)       Date:  2019-08-06

7.  Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.

Authors:  Marius Andreas Koslik; Justa Friebus-Kardash; Falko Markus Heinemann; Andreas Kribben; Jan Hinrich Bräsen; Ute Eisenberger
Journal:  Front Med (Lausanne)       Date:  2022-01-31

8.  Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Authors:  Olfat Shaker; Heba Bassiony; Maissa El Raziky; Samer S El-Kamary; Gamal Esmat; Akmal M El-Ghor; Mona M Mohamed
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

9.  Lack of serologic evidence to link IgA nephropathy with celiac disease or immune reactivity to gluten.

Authors:  Sina Moeller; Pietro A Canetta; Annette K Taylor; Carolina Arguelles-Grande; Holly Snyder; Peter H Green; Krzysztof Kiryluk; Armin Alaedini
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

10.  Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.

Authors:  Justa Friebus-Kardash; Ejona Nela; Birte Möhlendick; Andreas Kribben; Winfried Siffert; Falko Markus Heinemann; Ute Eisenberger
Journal:  Transplantation       Date:  2021-07-01       Impact factor: 5.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.